“Mirum Pharmaceuticals has finalized its acquisition of Bluejay Therapeutics in a deal valued at up to $820 million, incorporating the late-stage asset brelovitug into its portfolio for treating chronic hepatitis delta virus; the move expands Mirum’s expertise in rare liver disorders, with Phase 3 trial data anticipated in the latter half of 2026 and potential market entry in 2027, supported by a $268.5 million private placement financing.”
Mirum Pharmaceuticals, a biopharmaceutical firm specializing in therapies for rare and severe liver diseases, has now integrated Bluejay Therapeutics into its operations following the closure of the acquisition. This strategic move positions Mirum to advance its mission in addressing unmet needs in viral and liver-related conditions, particularly through the addition of brelovitug, a promising monoclonal antibody candidate.
Brelovitug stands out as a fully human immunoglobulin G1 (IgG1) monoclonal antibody designed to target the surface antigen (HBsAg) present on both chronic hepatitis delta virus (HDV) and hepatitis B virus (HBV). Its mechanism of action involves neutralizing and clearing virions while depleting HBsAg-containing subviral particles, offering a dual approach to combating these interconnected infections. Chronic HDV, which requires HBV for replication, represents a particularly aggressive form of viral hepatitis, leading to rapid disease progression, cirrhosis, and liver failure in affected individuals. With an estimated 230,000 people impacted in the United States and Europe alone, and over half facing liver-related mortality within a decade of diagnosis, the absence of approved treatments in the U.S. underscores the urgency of innovative solutions like brelovitug.
The asset has garnered significant regulatory recognition, including Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for HDV treatment, as well as PRIME and Orphan designations from the European Medicines Agency (EMA). These accolades highlight its potential to address a critical gap in care for a rare condition that disproportionately affects vulnerable populations, such as those with underlying HBV infections.
Clinical development for brelovitug is well advanced, with the global AZURE Phase 3 registrational program currently underway. This comprehensive initiative encompasses multiple open-label studies evaluating a combined endpoint of virologic response (reduction in HDV RNA) and biochemical response (normalization of liver enzymes like ALT). Interim results from earlier Phase 2 trials have been encouraging, demonstrating a 100% virologic response rate in HDV RNA clearance at Week 48, alongside substantial improvements in ALT levels for up to 82% of participants achieving the combined endpoint. The safety profile appears favorable, with the most frequently reported adverse event being mild injection-site erythema, and no serious treatment-related issues observed across the cohorts.
Topline data from the AZURE program are projected for the second half of 2026, paving the way for potential Biologics License Application (BLA) submission to the FDA and subsequent commercial launch in 2027. This timeline aligns with Mirum’s broader strategy to build a robust pipeline that leverages its existing commercial infrastructure in rare liver diseases. Mirum already markets therapies for conditions like progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome, providing a foundation for efficient integration and market access for brelovitug upon approval.
Financially, the acquisition was structured to balance upfront commitments with performance-based incentives. Mirum secured all outstanding shares of Bluejay through a mix of cash and its own common stock, with the initial consideration totaling approximately $620 million—comprising $250 million in cash and $370 million in stock valued at $71.2085 per share. Additional upside for Bluejay stakeholders includes tiered sales-based milestone payments that could reach $200 million, contingent on brelovitug’s commercial success, bringing the total potential value to $820 million.
To fund the transaction and support ongoing development, Mirum executed concurrent private placement financings, attracting investments from a syndicate of existing and new healthcare-focused investors. These efforts yielded gross proceeds of about $268.5 million, with shares priced at $68.48 each (or $68.4799 per pre-funded warrant share, adjusted for the nominal exercise price). The capital infusion is earmarked for advancing the AZURE trials, preparing for regulatory filings, and gearing up for commercialization, including building out sales teams and supply chains tailored to the HDV patient population.
Beyond brelovitug, the acquisition opens doors to Bluejay’s earlier-stage investigational programs in viral hepatitis and liver disorders. Mirum is actively assessing strategic options for these assets, which could involve internal development, partnerships, or out-licensing to maximize value. This diversification strengthens Mirum’s position in the rare disease space, where it already pursues volixibat for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), as well as MRM-3379 for Fragile X syndrome (FXS). The combined pipeline now spans multiple modalities and indications, enhancing Mirum’s ability to deliver transformative therapies.
Market analysts have responded positively to the deal’s completion, viewing it as a “steal” given brelovitug’s advanced stage and the underserved HDV market. HC Wainwright & Co. recently reiterated a Buy rating on Mirum’s stock, elevating its price target from $102 to $130, reflecting confidence in the expanded pipeline’s revenue potential. Projections for Mirum’s 2026 revenue now range from $630 million to $650 million, driven by growth in existing products and anticipated contributions from new assets like brelovitug.
In terms of stock performance, Mirum’s shares (NASDAQ: MIRM) have shown resilience amid the acquisition news. Following an initial dip upon the December 2025 announcement, the stock has rebounded, closing recently at $94.29 before opening higher at $96.17, with a current trading price around $96.92. This represents a market capitalization exceeding $5 billion, supported by a 52-week range from $36.88 to $98.49 and average daily volume in the hundreds of thousands. The uptick suggests investor optimism about the long-term synergies and growth prospects.
To illustrate the expanded pipeline post-acquisition, consider the following overview:
| Asset | Indication | Development Stage | Key Milestones |
|---|---|---|---|
| Brelovitug | Chronic HDV | Phase 3 (AZURE) | Topline data 2H 2026; Potential BLA 2027 |
| Volixibat | PSC | Phase 3 | Ongoing enrollment; Data readout pending |
| Volixibat | PBC | Phase 2b | Interim analysis expected |
| MRM-3379 | FXS | Preclinical/Early Clinical | Advancement to Phase 1 targeted |
| Legacy Bluejay Programs | Viral Hepatitis/Liver Disorders | Investigational | Strategic review underway |
This table highlights how the acquisition not only adds a near-term catalyst in brelovitug but also complements Mirum’s existing efforts in cholestatic liver diseases.
Key strategic benefits of the deal include enhanced global leadership in rare liver disorders, where Mirum’s established expertise in pediatric and adult hepatology can accelerate brelovitug’s path to patients. The integration of Bluejay’s team brings specialized knowledge in virology, bolstering Mirum’s R&D capabilities. Furthermore, the transaction aligns with broader industry trends toward consolidation in biotech, where companies seek to acquire late-stage assets to mitigate development risks and capitalize on high-value orphan markets.
Financially, the deal is accretive, with brelovitug poised to tap into a market where current standard-of-care options are limited to off-label interferons, which carry significant side effects and low efficacy. Peak sales estimates for brelovitug could exceed $500 million annually, given the global HDV burden estimated at 12-15 million cases worldwide, though focused initially on the U.S. and European markets.
Operationally, Mirum plans to leverage its commercial platform, which includes direct-to-patient support programs and relationships with hepatology specialists, to ensure a smooth launch. Challenges such as patient identification and diagnosis—HDV often goes undetected without specific testing—will be addressed through awareness campaigns and diagnostic partnerships.
Overall, this acquisition marks a pivotal step for Mirum in scaling its impact on rare diseases, with brelovitug representing a high-potential addition that could redefine treatment paradigms for HDV.
Disclaimer: This news report provides informational tips based on publicly available sources.